Immunization with Leishmania Vaccine‐Alum‐BCG and Montanide ISA 720 Adjuvants Induces Low‐Grade Type 2 Cytokines and High Levels of IgG2 Subclass Antibodies in the Vervet Monkey (Chlorocebus aethiops) Model
Open Access
- 4 August 2012
- journal article
- research article
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 76 (5), 471-477
- https://doi.org/10.1111/j.1365-3083.2012.02764.x
Abstract
The availability of hundreds of adjuvants has prompted a need for identifying rational standards for the selection of adjuvant formulation based on sound immunological principles for human vaccines. As cytokines elaborated by activated T cells are required for the regulation of isotype switch during B-cell development, a study of Th2 cytokines and subclass distribution of the antibodies may shed new light on the processes involved in the polarization of the immune responses during vaccination studies. The aim of this study was to identify an appropriate Leishmania vaccine adjuvant based on low Th2 cytokine and high value IgG2 antibody responses. Groups of vervet monkeys were immunized with Leishmania donovani sonicate antigen (Ag) alone or in conjunction with alum-BCG (AlBCG), monophosphoryl lipid A (MPL) or montanide ISA 720 (MISA) as adjuvants. Following three time point intradermal injections on days 0, 28 and 42, IL-4, IL-10 and IgG antibody subclasses were quantified by enzyme-linked immunosorbent assay (ELISA) and data analysed by one-way analysis of variance, Tukey–Kramer test and Spearman’s rank correlation analysis. Results indicated relatively higher IL-4 and IL-10 cytokine responses following MPL + Ag as compared to AlBCG + Ag or MISA + Ag immunization. There was a positive significant correlation between IL-4 and IL-10 levels (r = 1.000; P = 0.0167). Significantly higher IgG2 antibody responses were associated with either AlBCG + Ag or MISA + Ag as compared to MPL + Ag immunization (P < 0.05). The study concludes that both AlBCG and MISA may be used in Leishmania vaccine studies that favour low Th2 cytokine and strong IgG2 antibody responses.Keywords
This publication has 23 references indexed in Scilit:
- Leishmania donovani whole cell antigen delivered with adjuvants protects against visceral leishmaniasis in vervet monkeys (Chlorocebus aethiops)Journal of Biomedical Research, 2012
- A review of adjuvants for Leishmania vaccine candidatesJournal of Biomedical Research, 2010
- CD8 cytotoxic T cells in cutaneous leishmaniasisParasite Immunology, 2007
- Leish-111f, a Recombinant Polyprotein Vaccine That Protects against Visceral Leishmaniasis by Elicitation of CD4+T CellsInfection and Immunity, 2007
- A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteersVaccine, 2001
- Visceral leishmaniasis in Somalia. Significance of IgG subclasses and of IgE responseImmunology Letters, 1996
- Determinants of the immune response in visceral leishmaniasis: Evidence for predominance of endogenous interleukin 4 over interferon-γ productionClinical Immunology and Immunopathology, 1990
- Lymphokine Control of In Vivo Immunoglobulin Isotype SelectionAnnual Review of Immunology, 1990
- Antibody isotypes in human schistosomiasis mansoniParasite Immunology, 1987
- Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis.JCI Insight, 1985